Forward
Techno-Blast
Wednesday, June 22, 2016  |  Volume 8 / Number 13  |  A Production of the BioProcessing Journal
ISBioTech 4th Fall Meeting
Register and Attend Talks From All Three Programs!
Business For Sale
Biotech and Pharmaceutical Contract Manufacturing Organization (CMO)
Includes leased facilities, equipment, and procedures.

Click here for more information.
Career Development
PREP
29th International Symposium
July 17–20, 2016
Philadelphia, Pennsylvania USA
MIT
Downstream Processing Course
July 25–29, 2016
Cambridge,
Massachusetts USA
ESACT
Cell Culture-Based Viral Vaccines – First Edition
September 21–23, 2016
Animal Cell Technology Course – Sixth Edition
September 25–29, 2016
Llafranc, Costa Brava, Spain
Cell and Gene Therapy
ESGCT Annual Meeting
October 18–21, 2016
Florence, Italy
ISPPP
International Symposium
on the Separation
of Proteins, Peptides and Polynucleotides (ISPPP)
November 6–9, 2016
Salzburg, Austria
BioProcess Cuba
BioProcess Cuba
February 20–24, 2017
Camagüey, Cuba
Techno-Blast Masthead
A possible therapy for macular degeneration is to transplant retinal pigment epithelial (RPE) cells on bioengineered, nanofibrous scaffolds into patients’ eyes. Here a pseudo-colored image of the RPE cells growing out over the nanofibers can be seen. Each cell has thousands of “tongues” and “rods” protruding from its surface that would naturally support rod and cone cells in the eye.

Courtesy of Cellular Dynamics International, a FUJIFILM company.
Suggested Reading
Development and Assessment of a Novel Device for the Controlled,
Dry Thawing of Cryopreserved Cell Products
By John M. Baust, PhD et al., CPSI Biotech
Sponsored Link
The Allegro™ STR single-use bioreactors
Want to dramatically improve utilization of chromatography sorbents, especially at higher titers? Pall's BioSMB platform is the first disposable flow path, continuous multi-column chromatography solution. Unique to biopharmaceuticals, the system is designed to boost productivity and optimize the use of chromatography sorbents. Reducing space requirements and costs, the BioSMB system delivers a scaleable, flexible and single-use path to multi-column applications, and peerless productivity per unit area of manufacturing space. It is ideal for bind and elute chromatography.

Pall Life Sciences
Email: biopharm@pall.com
www.pall.com/continuous
Products & Services
National Roadmap for Advanced Cell Manufacturing Shows Path to Cell-Based Therapeutics
Over the past decade, new and emerging cell-based technologies have been developed to manage and possibly cure many conditions and diseases. Research has demonstrated the value of cell therapies using adult stem cells and immune system cells. However, in order for these treatments to become more widely available, the cell therapeutics community has to develop the capability for advanced, large-scale manufacturing of high-quality and consistent living cells.
National Roadmap for Advanced Cell Manufacturing
To advance that goal, the Georgia Research Alliance (GRA) and the Georgia Institute of Technology (Georgia Tech) launched the National Cell Manufacturing Consortium (NCMC) which recently released the National Roadmap for Advanced Cell Manufacturing. The roadmap has been designed to chart the path to large-scale manufacturing of cell-based therapeutics for use in a broad range of illnesses.

Established in 2014, the NCMC is an industry-driven consortium with strong support and involvement from more than 60 representatives including cell manufacturing experts from industry, academic research, clinical good manufacturing practice (GMP) centers, government agencies, nonprofit organizations, and private foundations. The consortium's establishment and development of the 10-year national roadmap was sponsored by the National Institute of Standards and Technology (NIST) through an Advanced Manufacturing Technology (AMTech) grant.

For more information and to view the roadmap, please visit cellmanufacturingusa.org.
The New Shortcut to Protein Expression
ibidi GmbH introduces Fuse-It-mRNA to enable immediate mRNA transfer and a highly efficient protein synthesis in difficult-to-transfect cells. This innovative reagent offers an easy and efficient method for endosome-independent mRNA transfer, accompanied by extremely low cytotoxicity, in primary cells or stem cells.
Fuse-It-mRNA The Fuse-It liposomal carrier, which includes the mRNA, simply fuses with the cell membrane and then releases the mRNA directly into the cytoplasm. mRNA translation starts immediately, without the interfering processes of endocytosis, lysosomal degradation, or mitosis. Based on the charge of natural cell membranes, Fuse-It-mRNA liposomes are able to effectively fuse with most cell types. Cell lines, non-proliferating cells, and a broad spectrum of difficult-to-transfect primary cells can directly translate the mRNA in the cytosol. Membrane fusion with Fuse-It-mRNA results in fast and highly efficient protein expression with no risk of genomic integration.

For more information, please visit ibidi.de.
Career Development
CASSS
CMC Strategy Forum
Summer
July 18–19, 2016
Gaithersburg, Maryland USA
CMC Strategy Forum
Latin America
September 5–6, 2016
Mexico City, Mexico
Phacilitate
Cell & Gene Therapy / Immunotherapy
September 21–22, 2016
Berlin, Germany
BEBPA
9th Annual Bioassay Conference
September 28–30, 2016
Dubrovnik, Croatia
JAACT
The 29th Annual and International Meeting
of the Japanese Association
for Animal Cell Technology
November 9–12, 2016
Kobe, Japan
BPJ Publishing
BioProcessing Journal BioProcessing Journal BioProcessing Journal
Advertising
Economize by combining Techno-Blast and BioProcessing Journal advertising into one package.

Request a media kit today!
Did a colleague forward this to you? Subscribe here. While we'd hate to see you go, you can unsubscribe instantly.

[[tracking_beacon]]